Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03937635
Title Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications

multiple myeloma

Therapies

Dexamethasone + Lenalidomide

Daratumumab + Dexamethasone + Lenalidomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.